Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592418 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
A Phase 2 study, sponsored by AIM ImmunoTech.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT05592418 is a Phase 2 study that has completed, run by AIM ImmunoTech. The registered enrollment target is 80 participants.
The verdict
NCT05592418, a Phase 2 study, has completed, sponsored by AIM ImmunoTech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
Interventions
- DRUG Rintatolimod
- OTHER Placebo / Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05592418
The ClinicalTrials.gov registry entry for NCT05592418 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIM ImmunoTech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rintatolimod is the first listed.
NCT05592418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05592418 about?
NCT05592418 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions". The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
What is the current status of trial NCT05592418?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-06-30. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT05592418?
The interventions under investigation include: Rintatolimod (DRUG), Placebo / Normal Saline (OTHER).
Who is sponsoring clinical trial NCT05592418?
This trial is sponsored by AIM ImmunoTech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.